February 11, 2020 • WindMIL Therapeutics and Providence Cancer Institute Announce Collaboration to Collect Bone Marrow from Patients with Breast Cancer to Develop Marrow-Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and Providence Cancer Institute today announced that the first patient has been identified in an investigator-sponsored study for the collection of bone marrow from patients with breast cancer. The study will evaluate generating marrow-infiltrating lymphocytes (MILs™) for patients through WindMIL’s proprietary cellular activation and expansion process. The study is being conducted at the […]

February 5, 2020 • WindMIL Therapeutics Announces Cancer Immunotherapy Pre-Clinical Research Collaboration with University of Pennsylvania

WindMIL Therapeutics today announced a collaborative pre-clinical research partnership with University of Pennsylvania (Penn) to explore novel chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) in hematological and solid tumor model settings. The collaboration will leverage WindMIL’s and Penn’s respective expertise to conduct pre-clinical comparisons of the characteristics and functionality of CAR-T and CAR-MIL products.

January 7, 2020 • WindMIL Therapeutics Announces Expansion of Leadership Team

WindMIL Therapeutics today announced the expansion of its leadership team with the appointment of Karen LaRochelle as Senior Vice President, Corporate & Business Development and the promotion of Patrick Dougherty to Senior Vice President, Strategy, Planning & Operations.

December 19, 2019 • WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to evaluate the safety and efficacy of WindMIL Therapeutics’ marrow-infiltrating lymphocytes (MILs™) in combination with Bristol-Myers Squibb’s nivolumab (Opdivo®), a PD-1 immune checkpoint inhibitor, in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who […]

December 11, 2019 • WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

WindMIL Therapeutics today announced that the first patient has been dosed in a Phase 2a clinical trial to determine the safety and efficacy of MILs alone and in combination with an anti-PD-1 in patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) who are refractory to or have relapsed on an anti-PD-1-containing […]

December 9, 2019 • WindMIL Therapeutics to Present Data Demonstrating Superior Efficacy of CAR-T cells using Marrow-Infiltrating Lymphocytes (CAR-MILs™) Compared to Peripheral Blood Lymphocytes at the 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics will present new data in a poster presentation on Monday, December 9, 2019, at the 61st American Society of Hematology Annual Meeting and Exposition (ASH), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) possess superior anti-tumor immunity compared to traditional CAR-T cells engineered using peripheral blood lymphocytes (CAR-PBLs).

November 6, 2019 • WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition

WindMIL Therapeutics announced today that data demonstrating the efficacy of chimeric antigen receptor (CAR) T cells developed using MILs (CAR-MILs) in comparison to peripheral blood lymphocytes has been selected for a poster at 61st American Society of Hematology (ASH) Annual Meeting and Exposition. ASH 2019 will be held December 7-10 at the Orange County Convention Center […]

November 5, 2019 • WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to Peripheral Blood Counterparts at 34th Annual Meeting of the Society for Immunotherapy of Cancer

WindMIL Therapeutics will present new data in a poster presentation on Saturday, November 9, 2019, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), demonstrating that chimeric antigen receptor (CAR)-engineered MILs (CAR-MILs™) are more polyfunctional and produce higher levels of pro-inflammatory chemokines and cytokines associated with antitumor activity than CAR-T cells engineered […]

October 15, 2019 • WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with gliomas. The study will evaluate generating marrow infiltrating lymphocytes (MILs™) for these patients through WindMIL’s proprietary cellular activation and expansion process. The study is […]

September 9, 2019 • WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory & Quality Systems

WindMIL Therapeutics has announced the appointment of Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems. In this role, Dr. Patel will provide strategic vision and executional leadership for regulatory and quality functions and establish associated operations.